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OBJECTIVE—Two lower-extremity diseases (LEDs), including peripheral neuropathy and
peripheral vascular disease (PVD), are leading causes of disability in the U.S. Although LEDs can
be complications of diabetes, their prevelances and risk factors apart from diabetes are poorly
described. This study describes the prevalence of LEDs and examines the association of obesity
and cardiometabolic clustering in a population-based sample.
RESEARCH DESIGN AND METHODS—Adults aged $40 years (n = 2,514) were eval-
uatedinthe2001–2004NationalHealthandNutritionExaminationSurveyforclusteringoftwo
or more cardiometabolic characteristics, including elevated triglycerides or plasma glucose, low
HDL cholesterol levels, increased waist circumference, or hypertension. Clustering was com-
bined with BMI (dichotomized at $30 kg/m
2)t og e n e r a t et h r e eg r o u p s :o b e s e( w i t ho rw i t h o u t
clustering); nonobese with clustering; and nonobese without clustering. Multivariate logistic
regression procedures incorporated the complex survey sampling design.
RESULTS—Overall, 9.0% of individuals had peripheral neuropathy alone, 8.5% had PVD
alone,and2.4%hadbothLEDs.Theobesegroupwasmorelikelytohaveperipheralneuropathy
(odds ratio 2.20 [95% CI 1.43–3.39]), PVD (3.10 [1.84–5.22]), and both LEDs (6.91 [2.64–
18.06]) compared with nonobese subjects without clustering. Within the nonobese group,
clustering increased the odds of peripheral neuropathy (1.50 [1.00–2.25]) and PVD (2.48
[1.38–4.44]) compared with no clustering.
CONCLUSIONS—Obesity and clustering markedly increased the likelihood of LEDs in this
sample and identiﬁed a group for whom preventive activities may reduce the risk of future
disability.
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P
eripheral vascular disease (PVD)
and peripheral neuropathy, both
lower-extremity diseases (LEDs),
are the leading cause of non–injury-
related amputations and disabilities in
the U.S. (1). Declines in physical func-
tioning and loss of independence later in
life are additional complications of these
conditions and speak to their public
health importance (2,3).
Peripheral neuropathy was tradition-
ally thought to develop in the diabetic
patient after many years of persistent
hyperglycemia. However, it is increas-
ingly recognized that many individuals
with diabeteshaveneuropathyatthetime
of their diagnosis (4), which suggests that
idiopathic neuropathy may be a marker
for prediabetes and thus may precede,
rather than follow, overt type 2 diabetes
(5–7).Considering measurementofLEDs
in the general population rather than in
diabetic-only populations acknowledges
that the general population may include
those with the transient hyperglycemia of
prediabetes. Transienthyperglycemiaisas-
sociatedwithincreasedreactiveoxygenspe-
cies and impaired nitric oxide–mediated
vasodilatation (6,8,9). Because neuropathy
is a microvascular condition, structural
damage to the microvasculature can ulti-
mately lead tonerve dysfunction,which is
central to the pathogenesis of peripheral
nerve injury (6).
The etiological link between the
lower-extremity conditions and meta-
bolic disorders, such as obesity, diabetes,
or cardiovascular disorders, may be a
function ofinsulinaction onvascular tone
(10). It is generally accepted that chronic
exposuretoabnormalplasmainsulinlevels
from chronic hyperglycemia leads to vas-
cular resistance in the larger vasculature.
However, there is growing appreciation
thatsmallervesselsmaybecomesimilarly
damaged giving rise to poor circulation
in the extremities and ultimately to pe-
ripheral neuropathy. In addition, this
process may begin well before the diag-
nosis of diabetes, which suggests the util-
ity of examining prediabetic individuals
for LEDs.
Apart from prediabetes, other impor-
tant metabolic abnormalities that may
predispose individuals to LEDs include
obesity, increased visceral or peripheral
fat, hypertension, elevated serum triglyc-
erides, and dyslipidemia, alone or in
combination (6,11–13). Although each
of these components in itself is a risk fac-
tor for cardiovascular disease and other
related outcomes such as PVD, their ag-
gregation or “clustering” may result in a
greater overall disease risk (14,15). Inde-
pendentof hyperglycemia,theremaybea
relationship between lipid abnormalities,
hypertension, and LEDs through their
shared contribution to the pathogenesis
of micro- and macrovascular dysfunction
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ORIGINAL ARTICLE(6,16,17). The relative contribution of
cardiometabolic clustering to the devel-
opment of LEDs is poorly characterized,
particularly in the general population.
This investigation examines the re-
lationship between LEDs, including PVD
and peripheral neuropathy, and cardio-
metabolic clustering, presuming that
LEDs would be positively associated
with cardiometabolic clustering among
nonobese adults aged $40 years. In ad-
dition, it was hypothesized that obese in-
dividualswouldhaveahigherprevalence
of LEDs compared with nonobese in-
dividuals, in those with and without
diabetes.
RESEARCH DESIGN AND
METHODS—The National Health
and Nutrition Examination Survey
(NHANES) III is an ongoing survey of
the National Center for Health Statistics
that includes both interview and physi-
cal examination components. Approxi-
mately 10,000 nationally representative
civilian adults and children are sampled
annually, with an oversampling of sub-
jects aged $60 years, African Americans,
and Hispanics. Additional documenta-
tion about the NHANES survey sampling
is available at the National Center for
Health Statistics Web site (18).
This investigation is based on data
from men and women aged $40 years
from two combined NHANES survey cy-
cles, 2001–2002 and 2003–2004. The
unweightedresponseratesforindividuals
who participated in the exam portion of
the survey cycles were 80 and 76%, re-
spectively. The study population for this
investigation consisted of 2,514 individ-
uals aged $40 years who were fasted at
the time of their examination.
LEDs include both PVD and periph-
eral neuropathy. All individuals aged
$40 years were eligible to participate in
the LED examination component of the
NHANES. Exclusion criteria included in-
dividuals.400 lb (because of equipment
limitations); those with bilateral leg am-
putations; any rash, open wounds, casts,
or dressings that interfered with testing;
or those who could not understand the
testing instructions. In addition, approx-
imately one-half of the individuals who
participated in the examination compo-
nent of the NHANES had a morning ap-
pointment time and were fasted for
at least 8 h. Individuals who were not
fasted were excluded from this report
to obtain interpretable and comparable
values.
Outcome variables
PVD was characterized using the systolic
blood pressure in the lower legs, mea-
sured in the posterior tibial vessel of both
ankles in ratio to the systolic blood
pressure measured in the brachial vessel
of the right arm. The resulting ankle-
brachialbloodpressureindex(ABPI)ratio
was used to characterize PVD, with an
ABPI ratio ,0.9 considered to be PVD.
Peripheral neuropathy was assessed
using Semmes-Weinstein monoﬁlament
standardized testing at three different
locations on the bottom of each foot. A
10-g ﬁlament force was applied, and the
participant was asked to indicate to the
examiner when they felt pressure. A
location was deﬁned as sensate if the ﬁrst
participant response was afﬁrmative or if
two of three tests at a particular location
yielded afﬁrmative responses. A location
was deﬁned as insensate if there was no
response from two administrations of the
monoﬁlament,two“unabletodetermine”
responses, or one nonresponse and one
“unable to determine” response for the
site. Peripheral neuropathy was deﬁned
as one or more insensate locations on ei-
ther foot.
Exposure variables
Obesity status and the clustering of car-
diovascular/metabolic measures were the
independent variables. Height (meters)
and weight (kilograms) were used to
calculate BMI (weight [in kilograms] di-
videdbythesquare ofheight[inmeters]),
and a BMI $30 kg/m
2 was used to deﬁne
obesity. The individual factors contribut-
ing to potential cardiometabolic cluster-
ing included measures of blood pressure,
lipids, carbohydrate metabolism, and a
proxy measure for visceral fat. These
factors and their corresponding risk
cut points have been used previously
(15,19). Four blood pressure measure-
ments were averaged. Hypertension was
deﬁned as having an average systolic
blood pressure $130 mmHg, an average
diastolic blood pressure $85 mmHg, or
taking prescription medication for high
blood pressure. Risk-level cut points for
HDL cholesterol and triglycerides were
,50 mg/dL in women (,40 mg/dL in
men) and $200 mg/dL, respectively. Di-
abeteswasdeﬁnedasafastingplasmaglu-
cose of $126 mg/dL or the current use of
diabetes medications. The risk cut point
for impaired fasting plasma glucose was
$110mg/dL;impairedfastingglucoseor
current use of diabetes medications de-
termined dysfunctional carbohydrate
metabolism The risk level for waist cir-
cumference was .88 cm in women and
.102 cm in men.
In this investigation, the presence of
at least two of the abnormal cardiometa-
bolic measures were used to characterize
cardiometabolic clustering and classify
individuals into one of three subgroups:
1) nonobese without clustering; 2)n o n -
obese with clustering; and 3)o b e s ew i t h
and without clustering. Because of the
small number of obese individuals with-
out dysfunctional cardiometabolic clus-
tering, we included all obese individuals
(with and without dysfunctional cardio-
metabolic clustering) in one group.
Statistical analysis
Fasting exam weights were used to calcu-
late weighted descriptive statistics for the
t o t a le l i g i b l es a m p l e( n = 2,514), with
continuous variables reported as means
andSEsandcategoricalvariablesreported
aspercentagesand SEs.Diseaseclassiﬁca-
tions used in these analyses were periph-
eral neuropathy alone (without PVD),
PVD alone (without peripheral neuropa-
thy), and the co-occurrence of both
LEDs.
After the development of descriptive
statistics by the three disease classiﬁca-
tions using a weighted subpopulation
analysis, bivariate logistic regression
models were used to provide compari-
sonsofindependentvariableswithineach
disease classiﬁcation. Next, unadjusted
logistic regression models were devel-
oped for LEDs and clustering groups,
using the nonobese group without clus-
tering as the referent group. Multivariate
logistic regression models were used to
assess the associations between the car-
diometabolic clustering group and LEDs
while accounting for sex, age, and race/
ethnicity covariates determined using a
priori evidence. First-order interactions
between cardiometabolic clustering
groups and covariates were considered
but not retained in the ﬁnal multivariate
models because the interaction terms
were not statistically signiﬁcant at the
a = 0.05 level.
SASversion 9.2softwarewas usedfor
statistical analysis to correctly specify
complex survey sampling weights, strat-
iﬁcation, and clustering for the two com-
bined NHANES cycles. As recommended
by the NHANES data documentation,
fasting examination weights from the
2001–2002 and 2003–2004 cycles were
eachdownweightedby0.5toaccountfor
combining the survey cycles.
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eral neuropathy was 11.5% (unweighted
prevalence 14.9%) and the prevalence of
PVD was 11.0% (unweighted prevalence
15.1%). A total of 9% (unweighted prev-
alence 11.3%) of individuals had periph-
eral neuropathy alone (Table 1), 8.5%
(unweighted prevalence 11.3%) had
PVD alone (Table 1), and 2.4% (un-
weighted prevalence 3.6%) had a combi-
nation of peripheral neuropathy and PVD
(Table 2).
A total of 15% of individuals were
classiﬁed as having diabetes. Individuals
without diabetes had a 9.7% prevalence
of peripheral neuropathy and a 9.4%
prevalence of PVD. The prevalence of
peripheral neuropathy alone and PVD
alone was 8.2 and 7.8%, respectively,
among individuals without diabetes. The
average age of the study sample was 56
years. Over 75% of participants were
white, and 55% reported more than a
highschooleducation.Meanbodyweight
was 75.3 kg for women and 88.7 kg for
men. Mean fasting plasma glucose was
105.60 mg/dL. More than 50% of indi-
viduals were hypertensive.
In comparison with individuals
without peripheral neuropathy, individ-
uals with peripheral neuropathy alone
weresigniﬁcantlymorelikelytobeolder,
to be men, to be African American or
black, and to be less educated. They had
higher waist circumference, BMI, glu-
cose,systolicbloodpressure,triglyceride
levels and greater prevalence of diabe-
tes and hypertension. They had lower
LDL cholesterol. Results are shown in
Table 1.
Compared with those without PVD,
individuals with PVD alone were more
likely to be older, to be women, to be
African American or black, and to be less
educated. They had higher waist circum-
ference, BMI, glucose, and systolic and
diastolic blood pressure and greater prev-
alence of diabetes and hypertension.
Individualswithbothperipheralneu-
ropathy and PVD were more likely to be
older, to be male, and to be heavier. They
had higher waist circumference, glucose,
and diastolic blood pressure but lower
LDL cholesterol levels. They also had a
higher prevalence of diabetes.
Inﬂuence of obesity cardiometabolic
clustering
Progressively greater prevalence of pe-
ripheral neuropathy alone was observed
with the three obesity-clustering groups.
The obese group and the nonobese group
with cardiometabolic clustering had in-
creased odds of peripheral neuropathy
alonecompared with the nonobesegroup
without clustering. This association re-
mained even after adjusting for sex, age,
and race/ethnicity (Table 3). Compared
with the nonobese group without cluster-
ing, the nonobese group with clustering
had 1.5 times the adjusted odds of pe-
ripheral neuropathy alone (odds ratio
[OR] 1.50 [95% CI 1.00–2.25]). Com-
pared with the nonobese group without
clustering,the obese group was twotimes
more likely to have peripheral neuropa-
thy alone (2.20 [1.43–3.39]) after adjust-
ing for sex, age, and race/ethnicity.
Table 1—Mean demographic and cardiometabolic factors of individuals aged ‡40 years by peripheral neuropathy* and PVD† status,
NHANES III, 2001–2004
Total
Peripheral
neuropathy
No peripheral
neuropathy P‡ PVD No PVD P‡
Proportion (%) 100 9.0 (0.7) 91.0 (0.7) 8.5 (0.8) 91.5 (0.8)
Age (years) 56.4 (0.3) 63.2 (0.7) 55.8 (0.4) ,0.0001 62.2 (1.2) 55.4 (0.3) ,0.0001
Sex (%)
Male 47.9 (1.0) 65.5 (3.1) 46.2 (1.0) ,0.0001 37.6 (3.8) 49.7 (1.2) 0.01
Female 52.1 (1.0) 34.5 (3.1) 53.8 (1.0) ,0.0001 62.4 (3.8) 50.3 (1.2) 0.01
Race/ethnicity (%)
White 77.8 (2.2) 78.8 (3.2) 77.7 (2.2) Reference 75.0 (3.8) 78.4 (2.1) Reference
Black 9.4 (1.2) 11.5 (2.0) 9.2 (1.2) 0.04 15.1 (2.8) 8.6 (1.1) ,0.0001
Other 12.8 (1.8) 9.7 (2.6) 13.1 (1.8) 0.06 9.9 (26) 12.9 (1.8) 0.01
Education (%)
Less than high school 18.9 (1.0) 22.2 (3.6) 18.5 (1.0) 0.7 27.6 (4.1) 17.1 (1.1) 0.4
High school or equivalent 25.7 (1.0) 25.0 (3.6) 25.8 (1.2) Reference 25.4 (3.1) 25.9 (1.2) Reference
More than high school 55.4 (1.5) 52.8 (4.8) 55.7 (1.5) 0.5 47.1 (3.5) 57.0 (1.7) 0.009
Weight (kg) 81.8 (0.5) 88.3 (1.6) 81.1 (0.5) ,0.0001 82.3 (1.6) 81.6 (0.6) 0.6
Waist circumference (cm) 99.0 (0.4) 105.5 (0.9) 98.4 (0.4) ,0.0001 102.5 (1.0) 98.5 (0.4) ,0.0001
BMI (kg/m
2) 28.5 (0.2) 29.4 (0.4) 28.4 (0.2) 0.01 29.8 (0.6) 28.3 (0.2) 0.0009
Glucose (mg/dL) 105.6 (0.8) 111.8 (2.4) 105.0 (0.8) 0.0005 110.2 (2.4) 104.8 (0.8) 0.002
Diabetes (%) 15.5 (0.9) 23.6 (3.1) 14.7 (1.0) 0.003 21.2 (3.0) 14.4 (0.9) 0.008
Lipid levels (mg/dL)
HDL cholesterol 52.9 (0.7) 50.3 (1.6) 53.1 (0.7) 0.2 53.3 (2.3) 52.7 (0.7) 0.8
LDL cholesterol 123.3 (1.2) 117.4 (3.5) 123.9 (1.1) 0.05 119.9 (2.7) 123.7 (1.2) 0.2
Triglycerides 161.1 (5.8) 187.0 (22.2) 158.5 (5.4) 0.05 167.2 (12.8) 160.1 (6.2) 0.5
Blood pressure (mmHg)
Systolic 127.6 (0.6) 131.4 (1.7) 127.2 (0.6) 0.02 136.7 (1.5) 126.2 (0.6) ,0.0001
Diastolic 72.6 (0.4) 70.9 (1.1) 72.8 (0.4) 0.1 69.7 (1.0) 73.2 (0.4) ,0.0001
Hypertension (%) 56.4 (1.5) 66.9 (3.9) 55.3 (1.6) 0.007 76.3 (3.3) 53.7 (1.6) ,0.0001
Data are means (SE) for continuous variables and percentage (SE) for categorical variables. *Peripheral neuropathy deﬁned as one or more insensate sites on either
foot. †PVD deﬁned as an ABPI ,0.90. ‡P values obtained from bivariate logistic regression. Statistical signiﬁcance considered P value ,0.05.
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NHANES lower-extremity disease and obesityA progressively greater prevalence of
PVD alone also was observed across the
obesity-clustering groups. Compared
with the nonobese group without car-
diometabolic clustering, the nonobese
group with cardiometabolic clustering
had 2.5 times the adjusted odds of having
PVD alone (OR 2.48 [95% CI 1.38–
4.44]). Compared with the nonobese
group without cardiometabolic cluster-
i n g ,t h eo b e s eg r o u pw a st h r e et i m e s
more likely to have PVD alone (3.10
[1.84–5.22]) after adjustment.
The strongest associations with car-
diometabolic clustering-obesity pheno-
types were observed for a combination
of both peripheral neuropathy and PVD
(Table3).Evenafteradjustment,thenon-
obesegroupwithclusteringwas2.6times
more likely to have LEDs (OR 2.62 [95%
CI 0.95–7.25]) and the obese group was
almost 7 times more likely to have LEDs
(6.91 [2.64–18.06]) compared with the
nonobese group without clustering.
Even after excluding individuals with
diabetes, progressively greater prevalence
of LEDs was observed across the obesity-
clustering group. Adjusting for sex, age,
and race/ethnicity, the nonobese group
with clustering was 1.5 times more likely
to have peripheral neuropathy alone (OR
1.51 [95% CI 1.00–2.27]), and the obese
group was almost twice as likely to have
peripheralneuropathy alone(1.92[1.27–
2.92]) compared with the nonobese
group without clustering. The nonobese
group with clustering was over twice as
likely to have PVD alone (2.36 [1.31–
4.25]) and the obese group was three
times more likely to have PVD alone
(3.16 [1.73–5.75]) compared with the
nonobese group without clustering. The
nonobese group with clustering also was
more likely to have both LEDs (1.57
[0.47–5.21]) and the obese group was
4.5 more likely to have both LEDs (4.55
[1.60–12.99]) compared with the non-
obese group without clustering.
CONCLUSIONS—Prevalences of
LEDs in excess of 10% were identiﬁed in
this representative sample of the U.S.
population, with 2.4% of the population
having a combination of both peripheral
neuropathy and PVD. In addition, al-
though diabetes was more frequent in
those with LEDs compared with the
general population, LEDs occurred apart
from a diagnosis of diabetes. Thus, al-
though the occurrence of LEDs is well
described in diabetic populations (12,20),
their frequency in the general population
indicates that these conditions deserve
greater clinical and public health atten-
tion.
To our knowledge, this is the ﬁrst
investigation of the association between
LEDs and the clustering of dysfunctional
cardiometabolic factors in the general
population and the potential exacerba-
tion generated by their co-occurrence
with obesity. Our results indicate that
even among the nonobese subjects, the
clustering of dysfunctional cardiometa-
bolic factors was associated with the in-
creased likelihood of having peripheral
neuropathy alone, PVD alone, and both
LEDs. The magnitude and direction of
our ﬁndings are similar to those of a
clinicalstudyamongpeoplewithdiabetes
in which there was a linear increase (P
value for trend ,0.05) in PVD and pe-
ripheral neuropathy as cardiometabolic
clustering increased (14). Identifying
LEDriskfactorsbeyondglycemiccontrol,
like cardiometabolic clustering, has im-
portant ramiﬁcations for future disease
prevention.
In our study, the aggregation of obe-
sity with cardiometabolic dysfunction was
associated with a modest increase in the
odds of both LEDs. However, the most
notable difference occurred in those who
presented simultaneously with both LEDs.
Being obese more than doubled the odds
of having PVD and peripheral neuropathy
compared with being lean with cardio-
metabolic clustering. These ﬁndings sug-
gest that obesity confers an additional risk
of individual LEDs over and above the
risk of LEDs present with cardiometabolic
dysfunction in the absence of obesity, but
the magnitude of the obesity contribution
with the co-occurring LEDs suggests a
particularly vulnerable population to the
obesity environment. Even after the exclu-
sion of individuals with diabetes, results
for the associations of LEDs with cardio-
metabolic clustering-obesity phenotypes
remained virtually unchanged for periph-
eral neuropathy alone and PVD alone and
only slightly attenuated for the combina-
tion of both peripheral neuropathy and
PVD.
Table 2—Mean demographic and cardiometabolic factors of individuals aged ‡40
years by both peripheral neuropathy* and PVD† statuses combined, NHANES III,
2001–2004
Both Neither P‡
Proportion (%) 2.4 (0.3) 97.6 (0.3)
Age (years) 66.4 (2.5) 56.2 (0.3) ,0.0001
Sex (%)
Male 74.1 (6.5) 47.3 (0.9) 0.0006
Female 25.9 (6.5) 52.7 (0.9)
Race/ethnicity (%)
White 82.4 (5.4) 77.7 (2.2) Reference
Black 9.2 (3.1) 9.4 (1.2) 0.6
Other 8.4 (3.7) 12.9 (1.8) 0.3
Education (%)
Less than high school 31.3 (7.4) 18.6 (1.0) 0.09
High school or equivalent 15.9 (5.7) 25.9 (1.0) Reference
More than high school 52.8 (8.0) 55.5 (1.5) 0.8
Weight (kg) 88.1 (3.4) 81.6 (0.6) 0.05
Waist circumference (cm) 105.9 (2.6) 98.9 (0.4) 0.006
BMI (kg/m
2) 29.4 (1.1) 28.5 (0.2) 0.4
Glucose (mg/dL) 114.6 (6.1) 105.4 (0.7) 0.02
Diabetes (%) 48.2 (8.9) 14.6 (0.9) ,0.0001
Lipid levels (mg/dL)
HDL cholesterol 47.9 (2.5) 53.0 (0.7) 0.1
LDL cholesterol 110.1 (4.5) 123.6 (1.2) 0.01
Triglycerides 174.2 (17.7) 160.7 (5.9) 0.4
Blood pressure (mmHg)
Systolic 128.6 (2.9) 127.6 (0.6) 0.7
Diastolic 64.6 (2.3) 72.8 (0.4) ,0.0001
Hypertension (%) 68.8 (6.7) 56.1 (1.6) 0.08
Data are means (SE) for continuous variables and percentage (SE) for categorical variables. *Peripheral
neuropathy deﬁned as one or more insensate sites on either foot. †PVD deﬁned as an ABPI ,0.90. ‡P values
obtained from bivariate logistic regression. Statistical signiﬁcance considered P value ,0.05.
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Ylitalo, Sowers, and HeeringaThe mechanisms by which obesity
confers a greater risk of LEDs await full
elucidation. Varying individual responses
to the levels and effects of the metabolic
products of adiposity, the adipocyto-
kines, may confer differing disease risks.
Adipocytokines may act as inﬂammatory
mediators in systemic inﬂammation and
vascular resistance in diabetes and car-
diovascular disease (21,22). Research in-
volving adiponectin, leptin, and resistin,
or the cytokines interleukin-6 and tumor
necrosis factor-a, may explain the epide-
miologic observation that obesity may be
associated with LEDs; thus, BMI alone
may be an incomplete proxy to represent
the obesity metabolic environment (22),
particularlyconsideringtheproportionof
unhealthy nonobese individuals (15).
This study had several strengths
and limitations. Although additional
cardiometabolic-obesity phenotypes were
of interest to us, the sample size (n ,50)
precluded a determination of whether
LEDs and obesity are associated indepen-
dently of clustering among individuals
with an LED exam. Therefore, we in-
cluded all obese individuals, with and
without dysfunctional cardiometabolic
clustering, in one group. It also is possible
that individuals were misclassiﬁed with
regard to diabetes status, particularly in
the obesity group. The cross-sectional na-
ture of this investigation not only pre-
cludes inferences of causality but also
precludesusfromunderstanding the tem-
poral order of the LEDs in those with co-
occurrence of both peripheral neuropathy
and PVD.
It is important to note that this report
may substantially underestimate the true
prevalence of peripheral neuropathy and
PVDbecauseoftheexclusioncriteriaused
by the NHANES. Individuals with bilateral
amputations, lesions, casts, or dressings
that interfered with testing procedures
were ineligible for LED assessments, as
were individuals who weighed .400 lb.
Because the NHANES protocol precludes
the use of individual identiﬁers, it is un-
clear how many individuals were ex-
cluded from the LED examination. The
presence of bilateral amputation, extreme
obesity,andalesionordressingislikelyto
be causally related to LEDs. In addition,
individuals with bilateral amputations are
more likely to have advanced disease be-
cause peripheral neuropathy and PVD are
the leading causes of noninjury amputa-
tions. Likewise, the presence of lesions or
dressings also could be an indication of
advanced disease. Although there may
be a potential for misclassiﬁcation of
LEDs beyond the exclusionary criteria,
monoﬁlament testing is a commonly
usedscreeningtoolinepidemiologicstud-
ies (4,20). It is possible that other factors,
such as inattention, temperature of the
feet, and thickness of the skin, may have
inﬂuenced the monoﬁlament results. For
example, obesity may increase the plantar
skin thickness of the feet, resulting in dif-
ferential misclassiﬁcation of peripheral
neuropathy by obesity status in this pop-
ulation, despite attempts by examiners to
avoid thickened or callus areas (18). Nev-
ertheless, compared with nerve conduc-
tion studies, monoﬁlament testing has
demonstrated sensitivities ranging from
57 to 93% and speciﬁcities ranging from
75 to 100% (23).
The large age range (40 to $85 years)
inourstudymayhaveledtoresidualcon-
founding by age despite the inclusion of
age in our statistical models. In addition,
for conﬁdentiality, the NHANES protocol
dictatesthatanyindividualovertheageof
85 years be considered “85” for the con-
tinuous age variable available in public
use datasets. Therefore, although the
maximumagewasreportedtobe85years
inthissample,thetruemaximumagewas
likely quite older and the reported mean
ages for the total eligible sample and for
the mean ages by disease status are likely
underestimates of the true means. There-
fore,itislikelythattheassociationbetween
age and LEDs would be strengthened by
including the true ages over 85 years.
It is a strength to consider three
different disease outcomes: peripheral
neuropathy alone (without PVD); PVD
alone (without peripheral neuropathy);
and the presence of both peripheral neu-
ropathy and PVD. The peripheral neu-
ropathy (alone) and PVD (alone) groups
are mutually exclusive. The beneﬁto f
these mutually exclusive groups pre-
cludes the possibility that insensate neu-
ropathy, as assessed by the monoﬁlament
testing in the NHANES III, is a conse-
quence of PVD or vice versa. When
peripheral neuropathy and PVD groups
were not mutually exclusive (results not
shown), results were of increased magni-
tude compared with the results presented
here.
Table 3—Unadjusted and adjusted prevalence ratios (95% CIs) of having peripheral neuropathy, PVD, or both by cardiometabolic
clustering and obesity categories in individuals aged ‡40 years, NHANES III, 2001–2004
Nonobese (BMI ,30 kg/m
2) Obese (BMI $30 kg/m
2)
Without clustering With clustering With and without clustering
n 503 1,148 809
Peripheral neuropathy (alone)*
Proportion [% (SE)] 4.9 (0.9) 9.7 (0.8) 10.9 (1.3)
Unadjusted prevalence ratio 1 (Reference) 2.07 (1.41–3.02) 2.35 (1.55–3.56)
Adjusted prevalence ratio† 1 (Reference) 1.50 (1.00–2.25) 2.20 (1.43–3.39)
PVD (alone)‡
Proportion [% (SE)] 3.2 (0.8) 9.6 (1.0) 10.3 (1.6)
Unadjusted prevalence ratio 1 (Reference) 3.25 (1.84–5.72) 3.52 (2.08–5.94)
Adjusted prevalence ratio† 1 (Reference) 2.48 (1.38–4.44) 3.10 (1.84–5.22)
LEDs (peripheral neuropathy and PVD combined)
Proportion [% (SE)] 0.6 (0.2) 2.3 (0.4) 3.9 (0.8)
Unadjusted prevalence ratio 1 (Reference) 4.06 (1.62–10.18) 7.05 (2.67–18.57)
Adjusted prevalence ratio† 1 (Reference) 2.62 (0.95–7.25) 6.91 (2.64–18.06)
*Peripheral neuropathy deﬁned as one or more insensate sites on either foot. †Adjusted for sex, age, and race/ethnicity. ‡PVD deﬁned as an ABPI ,0.90.
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NHANES lower-extremity disease and obesityThe early diagnosis of both PVD and
peripheral neuropathy has important
prognostic value because it may delay
the development of more debilitating
disease consequences (24,25). The utility
of the current study was the population-
based sampling scheme in identifying the
substantial prevalence of LEDs both with
and without the co-occurrence of diabe-
tes. To our knowledge, this is the ﬁrst
study to consider the association between
cardiometabolic clustering and obesity
with LEDs using a sample and study de-
sign representative of the U.S., enhancing
our ability to generalize these results to
individuals aged $40 years in the U.S.
PVD and peripheral neuropathy are
prevalent among individuals aged $40
years in the U.S., and the odds of having
LEDs increase with the presence of
cardiometabolic-obesity clustering. The
highprevalenceofLEDsinthegeneralpop-
ulation may warrant disease screening
outside of traditionally diabetic-only pop-
ulations because of the importance of
early detection. Future research using
longitudinal studies would allow charac-
terization of temporal relationships of
PVD, peripheral neuropathy, diabetes,
and increasing obesity. In addition, the
use of multiple obesity phenotypes
should be considered particularly for
studies of LEDs, because disease risk ap-
pears to be nonuniform across groups.
Understanding this phenomenon could
contribute to promoting the need for clin-
ical and public health screening as well as
multifactorial interventions beyond glyce-
mic control.
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